DOCSLIB.ORG

Bringing the Joslin Clinical Guidelines to the Diabetes Care Community

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bringing the Joslin Clinical Guidelines to the Diabetes Care Community 5 • 20 9 18 19 RESEARCH & LEADERSHIP Y E A R S JUNE 2018 VOL. 24 • NO. 7 IN THIS ISSUE Chapter 1. Clinical Guideline for Adults With CLINICAL GUIDELINES Diabetes, SP209. Chapter 2. Clinical Nutrition Guideline for Overweight and Obese Adults With Type 2 Diabetes (T2D) or Prediabetes, or Those at High Risk for Developing T2D, SP226. Chapter 3. Guideline for Detection and Management of Diabetes in Pregnancy, SP232. Chapter 4. Guideline for the Care of the Older Adult With Diabetes, SP240. Chapter 5. Clinical Guideline for Pharmacological Management of Adults With Type 2 Diabetes, SP253. Top: Joslin Diabetes Center, Boston, Massachusetts Bottom right: Patient education in the clinic, Joslin Diabetes Center Bottom left: A test to measure blood glucose For a message from the editors and a downloadable PDF of the Joslin Clinical Guidelines: ajmc.com/link/2921 Top, bottom right photos courtesy of: Joslin Diabetes Center FROM THE CHAIRMAN Collaborating With Joslin Diabetes Center to Save Lives PUBLISHING STAFF AT THE AMERICAN JOURNAL OF MANAGED CARE®, we say it often: Collaboration saves lives. Senior Vice President, Project Manager Bringing the most recent developments in research, clinical practice, and quality Managed Markets Andrea Szeszko measurement to a wider audience gives clinicians the ability to learn from one Jeff Prescott, PharmD Copy Chief another no matter where they practice. Associate Editorial Jennifer Potash ™ ™ Director With this issue of Evidence-Based Diabetes Management (EBDM ), we are taking Surabhi Dangi-Garimella, PhD Copy Editors Gayle Turim our long-term partnership with Joslin Diabetes Center to the next level as we publish Managing Editor Maggie Shaw the Joslin Clinical Guidelines. Dr Robert A. Gabbay, who serves as editor in chief of Mary K. Caffrey Paul Silverman EBDM ™, brought this idea to us last fall, and we shared his enthusiasm for bringing Assistant Editor Designer Samantha DiGrande Brianna Gibb the best practices of the world-renowned Joslin Diabetes Center to physicians, nurses, pharmacists, nutritionists, diabetes educators, and others who care for those SALES & MARKETING learning to manage this disease. Our editorial team worked with Dr Om P. Ganda, Director of Sales National Accounts chair of the Clinical Oversight Committee at Joslin, to organize updated editions of Gilbert Hernandez Associate the guidelines, which have been in use at Joslin for several years. Drs Ganda, Gabbay, Ryan O’Leary and their colleagues have ensured that the guidelines reflect the latest announce- OPERATIONS & FINANCE ments from the FDA, as clinicians have a growing array of therapeutic options for treating people with diabetes. Circulation Director Vice President, Finance Most people living with type 2 diabetes receive treatment from their primary care Jon Severn Leah Babitz, CPA physician, and it is our hope that sharing the Joslin Clinical Guidelines through the Controller Katherine Wyckoff leading source of managed care research will serve this group of physicians as well as health plans as they strive to deliver the best care possible. CORPORATE OFFICERS Sincerely, Chairman and CEO Vice President, Editorial Mike Hennessy, Sr Services and Production Michael J. Hennessy, Sr Kerrie Keegan Chairman and CEO Vice Chairman Jack Lepping Vice President, Digital Media President Jung Kim Mike Hennessy, Jr SP204 from the chairman SP232 Chief Creative Officer C hapter 3. Chief Financial Officer Jeff Brown SP205 from the E D itors Neil Glasser, CPA/CFE Guideline for Detection and Director, Human SP206 C L inica L OV ersi G ht Senior Vice President, Resources Management of Diabetes in Pregnancy Operations Shari Lundenberg committee / Wor K in G G ro U ps FLORENCE M. BROWN, MD; SUE-ELLEN ANDERSON- Tom Tolvé HAYNES, RD, CDE; ELIZABETH BLAIR, MSN, ANP-BC, SP208 OV erV ie W CDE, CDTC; SHANTI SERDY, MD; ELIZABETH HALPRIN, MD; ANNA FELDMAN, MD; KAREN O’BRIEN, MD; SUE GHILONI, RN, CDE; EMMY SUHL, MED, RD, CDE; SP209 JO-ANNE RIZZOTTO, MED, RD, CDE; OM P. GANDA, MD, C hapter 1. CHAIR, CLINICAL OVERSIGHT COMMITTEE; ROBERT A. GABBAY, MD, PHD, FACP; AND THE MEMBERS OF Clinical Guideline for Adults THE JOSLIN CLINICAL OVERSIGHT COMMITTEE, WITH With Diabetes ADMINISTRATIVE SUPPORT FROM BREDA CURRAN. SAMAR HAFIDA, MD; OM P. GANDA, MD, CHAIR, CLINICAL OVERSIGHT COMMITTEE; SP240 ROBERT A. GABBAY, MD, PHD, FACP; AND THE C hapter 4. 2 Clarke Drive, Suite 100 MEMBERS OF THE JOSLIN CLINICAL OVERSIGHT Cranbury, NJ 08512 • (609) 716-7777 COMMITTEE Guideline for the Care of the Older Adult With Diabetes Copyright © 2018 by Managed Care & Healthcare Communications, LLC SP226 MEDHA MUNSHI, MD; ELIZABETH BLAIR, MSN, ANP- The American Journal of Managed Care® ISSN 1088-0224 (print) & ISSN C hapter 2. BC, CDE, CDTC; OM P. GANDA, MD, CHAIR, CLINICAL 1936-2692 (online) is published monthly by Managed Care & Healthcare OVERSIGHT COMMITTEE; Clinical Nutrition Guideline for Communications, LLC, 2 Clarke Drive, Suite 100, Cranbury, NJ 08512. ROBERT A. GABBAY, MD, PHD, FACP; AND THE MEMBERS Copyright© 2018 by Managed Care & Healthcare Communications, LLC. Overweight and Obese Adults With Type OF THE JOSLIN GUIDELINES COMMITTEE All rights reserved. As provided by US copyright law, no part of this publication 2 Diabetes (T2D) or Prediabetes, or may be reproduced, displayed, or transmitted in any form or by any means, SP253 electronic or mechanical, without the prior written permission of the publisher. Those at High Risk for Developing T2D C hapter 5. For subscription inquiries or change of address, please call 888-826-3066. OSAMA HAMDY, MD, PHD; OM P. GANDA, MD, CHAIR, For permission to photocopy or reuse material from this journal, please CLINICAL OVERSIGHT COMMITTEE; Clinical Guideline for contact the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MELINDA MARYNIUK, MED, RD, CDE; Pharmacological Management of MA 01923; Tel: 978-750-8400; Web: www.copyright.com. Reprints of ROBERT A. GABBAY, MD, PHD, FACP; AND THE MEMBERS articles are available in minimum quantities of 250 copies. To order custom OF THE JOSLIN CLINICAL OVERSIGHT COMMITTEE Adults With Type 2 Diabetes reprints, please contact Jeff Prescott, The American Journal of Managed OM P. GANDA MD, CHAIR, CLINICAL OVERSIGHT Care®, [email protected]; Tel: 609-716-7777. The American Journal of COMMITTEE; ALISSA SEGAL, PHARMD, CDTC; ELIZABETH Managed Care is a registered trademark of Managed Care & Healthcare BLAIR, MS, ANP-BC, CDE, CDTC; RICHARD BEASER, MD; Communications, LLC. www.ajmc.com • Printed on acid-free paper. JASON GAGLIA, MD; ELIZABETH HALPRIN, MD; ROBERT A. GABBAY, MD, PHD, FACP; AND THE MEMBERS OF THE JOSLIN CLINICAL OVERSIGHT COMMITTEE SP204 JUNE 2018 AJMC.COM F R O M T H E E D ITORS Bringing the Joslin Clinical Guidelines to the Diabetes Care Community WITH THIS ISSUE OF Evidence-Based Detection and Management of Diabetes in Pregnancy; Diabetes Management™, we present the Guideline for the Care of the Older Adult With publication of the first installment of Diabetes; and the Clinical Guideline for Pharmacological the Joslin Clinical Guidelines, which Management of Adults With Type 2 Diabetes. With this are the principles that influence our installment, we have covered the major issues that most clinical behavior every day at Joslin physicians, registered dietitians, certified diabetes educa- Diabetes Center and our affiliates and tors, nurse practitioners, physician assistants, and phar- partners around the world. Although macists will encounter in clinical practice. The Clinical some sections of the guidelines have Guideline for Pharmacological Management of Adults GANDA been in use for years, our collaboration With Type 2 Diabetes has been revised to reflect recent with The American Journal of Managed scientific advances and regulatory developments that offer Care® represents our first cohesive effort more choices than ever for diabetes management. We to update and publish the guidelines repeat the position that Joslin Diabetes Center announced in a searchable format, one more easily earlier this year, when we concurred with the American shared with audiences beyond Joslin. Diabetes Association, the American Association of Clinical It is our hope that publication of the Endocrinologists, the Endocrine Society, and the American guidelines, in partnership with the Association of Diabetes Educators that those with diabetes leading peer-reviewed journal dedicated should aim for glycated hemoglobin of 7% or lower, not to research and leadership in health between 7% and 8%. outcomes, will bring the Joslin Clinical Is diabetes self-management challenging? Yes. But as GABBAY Guidelines into wider use. Through use of these guidelines reflect, and as we see at the Joslin Diabetes these guidelines, patients around the world can benefit from Center every day, self-management can succeed through the knowledge, research, and practices developed over more empowering our patients and engaging them alongside than a century of focus on the care of people with diabetes. appropriate pharmacotherapy. We hope this publication As explained in the overview, the Joslin Clinical serves as both a resource and an inspiration to providers Guidelines are developed by the Clinical Oversight who are struggling with what to do next for their patients. Committee at Joslin Diabetes Center, for which we serve We invite your feedback and look forward to sharing more as chair and ex-officio members, respectively. Our Clinical of the best practices developed at Joslin—so that individuals Oversight Committee
Load more

Recommended publications
  • With Featuring Moderated By
    and present “HOW TO LIVE WELL THROUGH 50 YEARS WITH DIABETES...TRUE STORIES!” PLUS – THE LATEST IN PROMISING ISLET CELL RESEARCH with GORDON C. WEIR, MD Senior Investigator, Section on Islet Biology and Regenerative Medicine, Diabetes Research and Wellness Foundation Chair, Joslin Diabetes Center Professor of Medicine, Harvard Medical School featuring A PANEL OF JOSLIN 50-YEAR MEDALISTS moderated by GEORGE L. KING, MD Chief Scientific Officer, Head of the Section on Vascular Cell Biology, Joslin Diabetes Center Founder of The Medalist Study Professor of Medicine, Harvard Medical School MONDAY, MAY 21, 2018 6:30 – 8:30pm WOMEN’S CLUB OF BETHESDA FREE ADMISSION RSVP AT (866) 293-3155 OR [email protected] WOMEN’S CLUB OF BETHESDA 5500 SONOMA ROAD BETHESDA, MARYLAND 20817 Conveniently located across the street from NIH and near I-495. Free parking available. The Diabetes Research and Wellness Foundation® is a 501c3 non-profit founded to help find the cure for diabetes and until that goal is achieved, to provide the care needed to combat the detrimental and life-threatening complications of this terrible disease. An Organization for People Who Live with Diabetes Every Day. Joslin Diabetes Center — dedicated to conquering diabetes in all of its forms — is the global leader in diabetes research, care and education. Joslin research is at the forefront of discovery aimed at preventing and curing diabetes. Joslin Diabetes Center is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. Find out more at diabeteswellness.net and joslin.org GORDON C. WEIR, MD Senior Investigator, Section on Islet Biology and Regenerative Medicine, Diabetes Research and Wellness Foundation Chair, Joslin Diabetes Center Professor of Medicine, Harvard Medical School Dr.
    [Show full text]
  • LMA Research Cores Poster Showcase 11/29/2018
    LMA Research Cores Poster Showcase 11/29/2018 Poster NRB # Location Core Name Institution Name 1 2nd floor Microfabrication/Microfluidics Core Facility Harvard Medical School 2 2nd floor Research Instrumentation Core Facility Harvard Medical School 3 2nd floor BioMEMS core Massachusetts General Hospital 4 2nd floor Nuclear Magnetic Resonance Core Dana Farber Cancer Institute 5 2nd floor East Quad NMR Core Harvard Medical School 6 2nd floor Confocal Imaging and IHC Core Beth Israel Deaconess Medical Center 7 2nd floor Histology Core Beth Israel Deaconess Medical Center 8 2nd floor Electron Microscopy Core Beth Israel Deaconess Medical Center 9 2nd floor Human Neuron Core Boston Children's Hospital 10 2nd floor Experimental Neurophysiology Core Boston Children's Hospital 11 2nd floor PreClinical MRI Core Beth Israel Deaconess Medical Center 12 2nd floor Radiology Research Core Boston Children's Hospital 13 2nd floor Electron Microscopy Facility Harvard Medical School 14 2nd floor PET core Massachusetts General Hospital 15 2nd floor Molecular Cancer Imaging Facility (MCIF) Dana Farber Cancer Institute 16 2nd floor PMB Microscopy Facility Massachusetts General Hospital 17 2nd floor BCH PCMM Microscopy Core Boston Children's Hospital 18 2nd floor NeuroTechnology Studio Brigham and Women's Hospital 19 2nd floor Harvard Center for Biological Imaging Harvard FAS 20 2nd floor Cellular Imaging Core (IDDRC) Boston Children's Hospital 21 2nd floor Image and Data Analysis Core Harvard Medical School 22 2nd floor Joslin Advanced Microscopy Core Joslin
    [Show full text]
  • Hypoglycemia January 2005
    Southeast Arizona EMS Region Standing Order Training Module Hypoglycemia January 2005 PURPOSE This SAEMS Standing Order Training Module has been developed to serve as a template for EMS provider training. The intent is to provide consistent and concise information to all providers practicing within the SAEMS Region. The content of the Training Module has been developed by the Protocol Development and Review Committee, and includes the specific Standing Order, resource and reference material, and instructions for completing the Training Module to obtain continuing education credit. One hour of SAEMS continuing education credit may be issued following successful completion of the module. OBJECTIVES: Upon completion of this learning module the participant will be able to: 1. Discuss the role of medical direction related to the use of Standing Orders. 2. List three benefits of Standing Orders. 3. Outline inclusion and exclusion criteria for this Standing Order. 4. Describe the communication process between the field and the receiving facility when a Standing Order is implemented. 5. List the elements of the dispatch radio relay. 6. List two reasons for direct facility (on-line) contact following implementation of a Standing Order. INSTRUCTIONS: 1. Read the accompanying information, Standing Order, and any additional reference material as necessary. 2. Complete the attached Posttest by ____________, and return with self addressed envelope to: _____________________________________ _____________________________________ _____________________________________ 3. A SAEMS CE Form will be issued to providers scoring greater than ____% on the Posttest. 4. Please contact __________________________________ for questions, suggestions, concerns. 1 Southeast Arizona EMS Region Standing Order Training Module Resource Material OVERVIEW The EMS system in Tucson has traditionally operated under direct medical control, requiring early radio contact with a base hospital physician on all prehospital encounters.
    [Show full text]
  • Nuha El Sayed, MD Dr. Gerald J. and Dorothy R. Friedman Fellow in Diabetes & Metabolism 2007 - 2009
    Nuha El Sayed, MD Dr. Gerald J. and Dorothy R. Friedman Fellow in Diabetes & Metabolism 2007 - 2009 Education Dr. El Sayed received her M.D. / M.B.B.Ch from Alexandria University, Egypt in 2001. She completed both her Internal Medicine Residency at Boston University’s Roger Williams Medical Center and a Clinical Research Fellowship in Obesity & Diabetes at the Joslin Diabetes clinic in 2007. She then completed her clinical training in Endocrinology, Diabetes and Metabolism as a Friedman Fellow at Tufts Medical Center in August 2009. She is now pursing a Masters in Clinical Investigation at the Sackler School of Biomedical Sciences at Tufts University. Former and Current Position(s) and Academic Interests Dr El Sayed is currently the Associate Director of the obesity clinic at the Joslin Diabetes Center in Boston, MA and an instructor in Medicine at Harvard Medical School. She is also on staff at Harvard Medical Faculty physicians. At the Joslin Diabetes clinic, Dr. El Sayed focuses on the care of overweight and obese type 2 diabetes patients. She leads a team of dietitians, exercise physiologists, nurses and behavioral therapists that focus on weight and intensive treatment of diabetes through the Joslin clinic’s Obesity Clinic. She is also involved in clinical research comparing medical to surgical weight loss in a randomized controlled trial. At Harvard Medical Faculty Physicians (HMFP), she works on various international projects involving diabetes care including projects in the Middle East and Asia where she designs, helps to implement Friedman Program in Diabetes & Metabolism at Tufts Medical Center, 2011 Report, Page 20 diabetes care models, programs and diabetes prevention initiatives, consults on various clinical activities, and coordinates the efforts of different Harvard institutions to facilitate the delivery of diabetes care worldwide.
    [Show full text]
  • Invention Disclosure Form
    Invention Disclosure Form For Internal Use Only Invention Number: Contact/Submission Info Please address all questions and return an electronic copy of the completed form to: Anthony Sutton, Senior Invention Administrator Email: [email protected] P: (617) 954-9721 When complete, please save F: (617) 954-9361 and hit ‘Submit’ button to (While filing form online, please have ‘insert’ key inactive) email directly for submission. 1. TITLE OF INVENTION 2. CATEGORY OF INVENTION Patent Material Software Copyright Trademark 3. DESCRIPTION OF THE INVENTION Describe the Invention to the extent known at this time. A. Key concepts of Invention, including nature, stage, purpose of operation of the invention including technical characteristics: (In addition, please attach manuscript, presentation, poster, or other documents, including any public disclosure documents) B. Distinguishing novel features of Invention: C. Envisioned commercial products or processes: INVENTION DISCLOSURE FORM 4. PUBLIC DISCLOSURE OR USE Public disclosure or use of an invention prior to filing a patent application will either limit or eliminate patent rights, dependent upon the extent of what was disclosed. A. Any past or future manuscript submission of Invention ? Yes, Date: No Expected date of online or paper publication B. Any past or future abstract, poster or talk of Invention? Yes, Date: No C. Any past or future journal publications (online and print)? Yes, Date: No D. Any past or future disclosures outside hospital of Invention? Yes, Date: Entity: No E. Any other past or future public disclosures? Type: Yes, Date: Entity: No F. Has Invention been used, tested or offered for sale? Yes, Date: No 5.
    [Show full text]
  • MDPH Investigation of Type 1 Diabetes in Weston, Wellesley, and Newton, Massachusetts
    MDPH Investigation of Type 1 Diabetes in Weston, Wellesley, and Newton, Massachusetts Suzanne K. Condon, Associate Commissioner Director, Bureau of Environmental Health April 20, 2010 Outline y Recap of EPHT diabetes surveillance y MDPH progress to date on investigation of type 1 diabetes in Weston, Wellesley, and Newton y Next steps 2 Environmental Public Health Tracking Diabetes Surveillance; K‐8 y Nurses/administrative staff report diabetes diagnoses to MDPH/BEH y Based on school health records y 603 CMR 23.7 (4)(H)(1976) MA Student Health Regulations and 105 CMR 210.000 Administration of Prescription Medications in Schools y Address access to student health records by school health personnel and local and state health department personnel, without the consent of the eligible student or parent, when such access is required in the performance of official duties. y Data collection began in 2007‐2008 school year y Currently collecting data for 2009‐2010 33 EPHT Diabetes Surveillance, cont. y Includes approximately 2100 public and private schools y Covers grades K through 8 4 MDPH Progress on Next Steps Outlined in June 2009 Work with school nurses to coordinate mailing to all parents of children diagnosed with diabetes to complement information from Ann Marie Kreft 5 MDPH Progress y Letters to School Nurses y FERPA reminder y May 2009 –1st mailing y Public Schools in 3 communities y Worked with nurse leaders y Nurses/school administrative personnel sent letters on MDPH’s behalf to parents of children with type 1 diabetes y Private Schools
    [Show full text]
  • Diabetes Education Programs Affiliated with Partners Healthcare
    Diabetes Education Programs affiliated with Partners HealthCare Referral is required for patient participation in diabetes self-management program. RSO Diabetes Education Program Accredited by Program Point of Contact Telephone Information Number BWPO Brigham Ambulatory Care ADA 617‐732‐9300 Samira Sheth 850 Boylston Street PHS Directory Chestnut Hill, MA 02467 BWPO 221 Longwood Avenue ADA 617‐732‐5666 Samira Sheth Boston, MA .2115 PHS Directory BWPO Brookside Community Health Center ADA 617‐522‐4700 Samira Sheth 3297 Washington Street PHS Directory Jamaica Plain, MA 02130 BWPO Southern Jamaica Plain Health Center ADA 617‐983‐4100 Samira Sheth 640 Centre Street PHS Directory Jamaica Plain, MA 02130 CAMC Cape Ann Medical Center ADA 781‐477‐3409 Anne Abramo, PT, DPT 1 Blackburn Drive PHS Directory Gloucester, MA 01930 CHA Cambridge Hospital ADA 617‐665‐1552 Ann Lindsay, RN, CDE 1493 Cambridge Street (Appointments) [email protected] Cambridge, MA 02139 617‐665‐2788 (Office/Voicemail) CHA Somerville Hospital ADA 617‐591‐4350 Ann Lindsay, RN, CDE 236 Highland Avenue (Appointments) [email protected] Somerville, MA 02143 617‐665‐2788 (Office/Voicemail) CRMA CRMA Framingham ADA 508‐848‐2190 Sandra Krafsig, RN, MS, CDE 600 Worcester Road PHS Directory Suite 404 Framingham, MA 01720 CRMA CRMA Marlborough ADA 508‐848‐2190 Sandra Krafsig, RN, MS, CDE 246 Maple Street PHS Directory Marlborough, MA 01752 CRMA CRMA Natick ADA 508‐848‐2190 Sandra Krafsig, RN, MS, CDE 67 Union Street PHS Directory Suite 410 Natick, MA 01760 EPHO Elizabeth
    [Show full text]
  • Quick Guides: Hypos
    1. INSULIN 2. MONITORING 3. HYPOS 4. SICK DAYS 5. MEDICATIONS 6. GLP-1RAs 7. NUTRITION Diabetes quick guides HYPOS Hypoglycaemia management What is a hypo? What are the common causes of hypo? Hypoglycaemia (also known as a hypo) occurs • Too much insulin or diabetes medication when your blood glucose levels (BGLs) drop too low. • Not enough carbohydrate in meal or snack Usually, a hypo is less than 4.0 mmol/L. • Extra (more than usual) activity or exercise For some people, for example the frail or elderly, • Alcohol a hypo may be less than 5.0 or 6.0 mmol/L. • Missed meal or fasting A hypo is a serious complication if not treated immediately. Reduced hypo awareness Why am I at risk of hypo? You may not always feel early warning signs and symptoms of a hypo. And over time you may feel You are at risk of hypo if you are taking a them even less. sulphonylurea (see Medications) or insulin. If your awareness of hypos reduces, you will need to monitor your BGLs very closely and regularly in What are the signs and order to be safe. symptoms of hypo? Driving Signs and symptoms can be very different for each person. Do not drive a vehicle if your BGL You may experience one or more of the following is less than 5.0 mmol/L. during a hypo: Check your BGL before you drive. 5.0mmol/L • trembling or shaking • feeling irritable Always take hypo treatment and your glucose meter • tingling • drowsiness or with you in the vehicle.
    [Show full text]
  • Institution Name Core Name Beth Israel Deaconess Medical Center
    Institution Name Core Name Beth Israel Deaconess Medical Center Electron Microscopy Core Beth Israel Deaconess Medical Center Histology Core Beth Israel Deaconess Medical Center Confocal Imaging and IHC Core Beth Israel Deaconess Medical Center PreClinical MRI Core Beth Israel Deaconess Medical Center Mass Spectrometry Core: Metabolomics, Lipidomics and Proteomics Beth Israel Deaconess Medical Center Glycomics Core Beth Israel Deaconess Medical Center PLI Registry and Biorepository Core Facility Beth Israel Deaconess Medical Center Animal Metabolic Physiology Core Beth Israel Deaconess Medical Center Preclinical Murine Pharmacogenetic Core facility Beth Israel Deaconess Medical Center Flow Cytometry Core Beth Israel Deaconess Medical Center Genomics and Proteomics Core: Biomarker Discovery Center Beth Israel Deaconess Medical Center Molecular Medicine Core Beth Israel Deaconess Medical Center Bioinformatics & Systems Biology Beth Israel Deaconess Medical Center X-ray Crystallography Core Facility Boston Childrens Hospital PCMM Flow Cytometry Core Boston Children's Hospital Human Neuron Core Boston Children's Hospital Experimental Neurophysiology Core Boston Children's Hospital Radiology Research Core Boston Children's Hospital BCH PCMM Microscopy Core Boston Children's Hospital Cellular Imaging Core (IDDRC) Boston Children's Hospital Viral Core Boston Children's Hospital Neurodevelopmental Behavior Core Boston Children's Hospital Mouse Gene Manipulation Core Boston Children's Hospital Animal Metabolic Physiology Core at Boston Children's
    [Show full text]
  • Diagnosis of Diabetes Mellitus
    DIAGNOSIS OF DIABETES MELLITUS The diagnosis of diabetes mellitus can be made based upon: • Random plasma glucose > 200 mg/dl and symptoms of diabetes (polyuria, polydipsia, ketoacidosis, or unexplained weight loss) OR • Fasting plasma glucose (FPG)* >126 mg/dl OR • Results of a 2-hour 75-g Oral Glucose Tolerance Test (OGTT)* > 200 mg/dl OR • Glycated hemoglobin* (A1C) > 6.5% ** * These tests should be confirmed by a repeat test, on a different day, unless unequivocally high **A glycated hemoglobin A1C (A1C) level of 6.5% or higher on 2 separate days is acceptable for diagnosis of diabetes. [1B]. However, some individuals may have an A1C < 6.5% with diabetes diagnosed by previously established blood glucose criteria. Therefore, presence of either criterion is acceptable for diagnosis. Those with an A1C of 5.7-6.4% are considered to have pre-diabetes and are at increased risk for diabetes, and should be treated with lifestyle changes and followed more frequently. A1C Diagnosis: See above section on Diagnosis of Diabetes Mellitus Note: The A1C may not be accurate in several settings, including pediatric and geriatric populations, patients with anemia or other blood disorders resulting in rapid turnover of red blood cells, in chronic liver and renal disease, following recent transfusions, or in the hospital setting. Interpret A1C results accordingly when determining treatment plans and goals. Follow-up visits: Check the A1C 2-4 times a year as part of the scheduled medical visit, with frequency dependent upon revision of the treatment program and the need to reinforce behavior changes. Increase frequency when therapy has changed and/or when glycemic goals are not met.
    [Show full text]
  • We Create Environments That Improve the Quality of Care
    We create environments that improve the quality of care Anna Jaques Hospital Lawrence Memorial Hospital McLean Hospital Arbour-Fuller Hospital Melrose-Wakefield Hospital North Shore Medical Center Atrius Health Harrington Memorial Hospital Spaulding Rehabilitation Hospital Worcester Medical Center Hartford HealthCare Riverside Health System Baystate Health Hartford Hospital Sentara Healthcare Baystate Franklin Medical Center William W. Backus Hospital Albemarle Hospital Baystate Medical Center Harvard Medical School BelleHarbour Beth Israel Deaconess Healthcare (CareGroup) Harvard Pilgrim Health Care Greenbrier HealthPlex Beth Israel Deaconess Hospital—Milton Hospital Corporation of America West Creek Campus Independence (formerly Bayside Hospital) Beth Israel Deaconess Medical Center Johns Hopkins University Hospital Kitty Hawk Medical Center BJC HealthCare Joslin Diabetes Center Leigh Hospital Barnes-Jewish Hospital Kaiser Permanente Norfolk General Hospital Bon Secours Health System King Faisal Specialty Hospital & Research Centre Princess Anne Hospital Good Samaritan Regional Medical Center Lahey Health Sentara Healthcare Corporate Headquarters Mary Immaculate Hospital Beverly Hospital Ambulatory Care Center Virginia Beach General Hospital Imaging Center at Reynolds Crossing Hunt Medical Center Southcoast Health St. Mary’s Hospital Lahey Clinic Charlton Memorial Hospital Boston Medical Center Winchester Hospital St. Luke’s Hospital Brockton Hospital Landmark Medical Center South County Hospital Bronx PsychiatricOur Center innovative
    [Show full text]
  • Alejandro Espaillat, M.D. Eye Physician & Laser Aesthetic
    Alejandro Espaillat, M.D. Eye Physician & Laser Aesthetic Surgeon Dr. Alejandro Espaillat is a Florida licensed Eye Physician & Surgeon trained at Harvard University and Brown University Schools of Medicine affiliated hospitals. Dr. Espaillat is a Diplomate in Aesthetic Medicine, as well as Board Certified from the American Academy of Aesthetic Medicine. He is an active surgeon who has performed thousands of successful ophthalmic and aesthetic surgical procedures including aesthetic facial neurochemical injections, dermal fillers, laser skin rejuvenation, advanced chemical peels, and plasma rich platelets, fibrin, and stem cells anti aging injections. Dr. Espaillat has been a member in good standing of the American Academy of Aesthetic Medicine, American Academy of Cosmetic Surgery, the American Society of Laser Medicine and Surgery, American Academy of Ophthalmology, and the American Society of Cataract and Refractive Surgery; as well as participated in the research and co-authorship of many published medical reports. ALEJANDRO ESPAILLAT, M. D. Demographic Information: Language Skills: Fluent in English and Spanish / US Citizen Office: South Florida Eye Institute ​ Main Office: 6233 N University Drive, Fort Lauderdale, Fl 33321 Telephone: 954-721-0000 email: [email protected] ​ Licensure and Certification: 2017 Board Certified Aesthetic Medicine, American Academy of Aesthetic Medicine 2017 Absorbable PDO Threads for skin rejuvenation & repositioning; AIAM 2017 Diplomate, Aesthetic Medicine, American Academy Aesthetic Medicine AAAM 2016 Certified, Aesthetic Medicine, American Acad. of Aesthetic Medicine AAAM 2002 Botox certification by Allergan 2001 Florida Board of Medicine (License ME81887) Education and Postdoctoral Training: July 1998- June 1999 Harvard University School of Medicine. Joslin Diabetes Center/Beetham Eye Institute. Boston, Massachusetts.
    [Show full text]